Search Results

Containing any of the words

Only of the type

Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) Drug Clinical Trial

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease Drug Clinical Trial

Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide Drug Clinical Trial

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia Drug Clinical Trial

"A 2-treatment period, randomized, placebo-controlled,multicenter parallel-group study to assess the safety ofQAW039 when added to existing asthma therapy in GINAsteps 3, 4 and 5 patients with uncontrolled asthma" Drug Clinical Trial

A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma Drug Clinical Trial

A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma Drug Clinical Trial

"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection" Drug Clinical Trial

Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection Drug Clinical Trial

A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes. Drug Clinical Trial